23:31 , Jul 14, 2017 |  BioCentury  |  Strategy

Transforming BeiGene

BeiGene Ltd.’s deal with Celgene Corp. for BGB-A317 does more than provide the Chinese biotech with a partner that can compete in the PD-1 space from a development and commercial perspective. It also marks a...
07:00 , May 9, 2016 |  BC Week In Review  |  Clinical News

BeiGene-283: Phase I data

Data from 29 evaluable patients with BRAF, K-Ras (KRAS) or neuroblastoma Ras viral (v-Ras) oncogene (NRAS) mutation-positive solid tumors in an open-label, dose-escalation, Australian and New Zealand Phase I trial showed that once-daily...
01:51 , Jan 21, 2016 |  BC Extra  |  Financial News

BeiGene sets IPO terms

Cancer company BeiGene Ltd. (Beijing, China) set terms for its IPO on NASDAQ and now hopes to sell 5.5 million ADSs at $22-$24. At $23, it would raise $126.5 million and be valued at $685.9...
08:00 , Nov 9, 2015 |  BC Week In Review  |  Clinical News

BeiGene-283: Phase I started

BeiGene began an open-label, dose-escalation, Chinese Phase I trial to evaluate BGB-283. BeiGene Ltd., Beijing, China   Product: BeiGene-283, BGB-283   Business: Cancer   Molecular target: BRAF   Description: Second-generation small molecule BRAF inhibitor   Indication: Treat...
01:27 , Oct 20, 2015 |  BC Extra  |  Financial News

BeiGene files for IPO on NASDAQ

BeiGene Ltd. (Beijing, China) filed to raise up to $100 million in an IPO of ADSs on NASDAQ underwritten by Goldman Sachs; Morgan Stanley; Cowen; and Baird. The company is running a Phase I study...
07:00 , Aug 24, 2015 |  BC Week In Review  |  Company News

BeiGene cancer news

BeiGene said it is establishing a biomanufacturing facility in BioBay, an innovation hub located in the Suzhou Industrial Park of Suzhou, China. It expects the cGMP facility to be completed by 2017. BeiGene said...
01:09 , Aug 21, 2015 |  BC Extra  |  Company News

BeiGene expands into BioBay

BeiGene Ltd. (Beijing, China) said it is establishing a biomanufacturing facility in BioBay, an innovation hub located in the Suzhou Industrial Park of Suzhou, China. It expects the facility to be completed by 2017. BeiGene...
00:53 , Aug 4, 2015 |  BC Extra  |  Company News

BeiGene gets CFDA approval to conduct clinical trial

BeiGene Ltd. (Beijing, China) said China FDA approved a clinical trial application (CTA) for BGB-283. The small molecule, second-generation BRAF inhibitor is BeiGene's first candidate to receive a CTA approval. BeiGene said it plans to...
07:00 , Jul 27, 2015 |  BC Week In Review  |  Clinical News

BeiGene-283: Phase Ib started

BeiGene began an open-label, Australian and New Zealand Phase Ib trial to evaluate once-daily oral BGB-283 in patients with solid tumors that harbor BRAF mutations and/or aberrations in the RAS-mitogen-activated protein kinase (MAPK) pathway. In...
07:00 , May 18, 2015 |  BioCentury  |  Finance

BeiGene going global

BeiGene Co. Ltd.'s existing and new investors have ponied up the second largest ever venture round for a Chinese biotech, as the company looks to globalize its clinical development and ramp up spending on a...